FACTOID # 25: If you're tired of sitting in traffic on your way to work, move to North Dakota.
 
 Home   Encyclopedia   Statistics   States A-Z   Flags   Maps   FAQ   About 
   
 
WHAT'S NEW
 

SEARCH ALL

FACTS & STATISTICS    Advanced view

Search encyclopedia, statistics and forums:

 

 

(* = Graphable)

 

 


Encyclopedia > Factor VII
coagulation factor VII
Identifiers
Symbol F7
Entrez 2155
HUGO 3544
OMIM 227500
RefSeq NM_000131
UniProt P08709
Other data
Locus Chr. 13 q34

Factor VII (formerly known as proconvertin) is one of the central proteins in the coagulation cascade. It is an enzyme (EC 3.4.21.21) of the serine protease class. The Entrez logo The Entrez Global Query Cross-Database Search System allows access to databases at the National Center for Biotechnology Information (NCBI) website. ... Hugo is a masculine name. ... The Mendelian Inheritance in Man project is a database that catalogues all the known diseases with a genetic component, and - when possible - links them to the relevant genes in the human genome. ... The National Center for Biotechnology Information (NCBI) is part of the US National Library of Medicine (NLM), which is a branch of the US National Institutes of Health. ... Swiss-Prot is a curated biological database of protein sequences created in 1986 by Amos Bairoch during his PhD and developed by the Swiss Institute of Bioinformatics and the European Bioinformatics Institute. ... Short and long arms Chromosome. ... Chromosome 13 is one of the 23 pairs of chromosomes in humans. ... A representation of the 3D structure of myoglobin, showing coloured alpha helices. ... Coagulation is a complex process by which blood forms solid clots. ... Ribbon diagram of the enzyme TIM, surrounded by the space-filling model of the protein. ... The Enzyme Commission number (EC number) is a numerical classification scheme for enzymes, based on the chemical reactions they catalyze. ... Crystal structure of Trypsin, a typical serine protease. ...

Contents

Physiology

The main role of factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels - normally not exposed to the bloodstream. Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), activated factor X and the FVIIa-TF complex itself. The most important substrates for FVIIa-TF are Factor X and Factor IX. Thromboplastin is a substance present in tissues, platelets, and leukocytes necessary for the coagulation of blood; in the presence of calcium ions thromboplastin is necessary for the conversion of prothrombin to thrombin, an important step in coagulation of blood. ... Factor X, also known by the eponym Stuart-Prower factor or as thrombokinase, is an enzyme ( EC 3. ... Factor IX (or Christmas factor or Christmas-Eve factor) is one of the serine proteases (EC 3. ...


The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants impairs its function. Tissue Factor Pathway Inhibitor (or TFPI) is a protein that can reversibly inhibit Factor Xa (Xa), and after it has inhibted Xa, the Xa-TFPI complex can then inhibit the FVIIa-TF complex. ... Vitamin K1 (phylloquinone). ... The liver is an organ present in vertebrates and some other animals. ... Warfarin (also known under the brand names of Coumadin, Jantoven, Marevan, and Waran) is an anticoagulant medication that is administered orally or, very rarely, by injection. ... An anticoagulant is a substance that prevents coagulation; that is, it stops blood from clotting. ...


Genetics

The gene for factor VII is located on chromosome 13 (13q34). For a non-technical introduction to the topic, see Introduction to Genetics. ... Figure 1: A representation of a condensed eukaryotic chromosome, as seen during cell division. ...


Role in disease

Deficiency is rare (congenital proconvertin deficiency) and inherits recessively.


Therapeutic use

Recombinant human factor VIIa (NovoSeven®, eptacog alfa [activated], ATC code B02BD08) has been introduced for use in uncontrollable bleeding in hemophilia patients who have developed inhibitors against replacement coagulation factor. Recombinant proteins are proteins that are produced by different genetically modified organisms following insertion of the relevant DNA into their genome. ... To meet Wikipedias quality standards, this article or section may require cleanup. ... Haemophilia or hemophilia is the name of any of several hereditary genetic illnesses that impair the bodys ability to control bleeding. ...


It is being increasingly used in uncontrollable hemorrhage.[1] The first report of its use was in an Israeli soldier with uncontrollable bleeding in 1999.[2] The rationale for its use in hemorrhage is, that it will only induce coagulation in those sites where tissue factor (TF) is also present. Still, O'Connell et al report an increased risk of deep vein thrombosis, pulmonary embolism and myocardial infarction in association with the use of rhFVIIa.[3] This article is about Deep-vein thrombosis. ... Acute myocardial infarction (AMI or MI), more commonly known as a heart attack, is a disease state that occurs when the blood supply to a part of the heart is interrupted. ...


According to a 2005 study, recombinant human factor VII improves outcomes in acute intracerebral hemorrhage.[4] ...


References

  1. ^ Roberts H, Monroe D, White G (2004). "The use of recombinant factor VIIa in the treatment of bleeding disorders". Blood 104 (13): 3858-64. PMID 15328151. 
  2. ^ Kenet G, Walden R, Eldad A, Martinowitz U (1999). "Treatment of traumatic bleeding with recombinant factor VIIa". Lancet 354 (9193): 1879. PMID 10584732. 
  3. ^ O'Connell K, Wood J, Wise R, Lozier J, Braun M (2006). "Thromboembolic adverse events after use of recombinant human coagulation factor VIIa". JAMA 295 (3): 293-8. PMID 16418464. 
  4. ^ Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M, Skolnick B, Steiner T (2005). "Recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 352 (8): 777-85. PMID 15728810. 

External links

  • Web site for novoseven-us.com

  Results from FactBites:
 
Factor VII deficiency (205 words)
Factor VII deficiency is an inherited disorder that causes abnormal blood clotting (coagulation), resulting from a deficiency of the plasma protein factor VII.
This disorder is caused by an inherited deficiency of factor VII, an important clotting protein.
The risk factor is a family history of bleeding.
Factor VII deficiency (301 words)
A series of complex chemical reactions involving these coagulation factors takes place very rapidly, forming an insoluble protein called fibrin that stops bleeding.
Bleeding episodes can be controlled with normal plasma, concentrates containing factor VII, or recombinant factor VII.
During bleeding episodes, frequent treatment is needed because the life span of factor VII is short.
  More results at FactBites »

 
 

COMMENTARY     


Share your thoughts, questions and commentary here
Your name
Your comments

Want to know more?
Search encyclopedia, statistics and forums:

 


Press Releases |  Feeds | Contact
The Wikipedia article included on this page is licensed under the GFDL.
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m